Summary of MTT assay results for primary AML samples treated with CEP-701 versus PKC412
Drug, dose . | WT FLT3 . | FLT3/ITD . |
|---|---|---|
| CEP-701 | ||
| 20 nM | 76.1 ± 2.0 | 66.4 ± 4.8 |
| 50 nM | 60.8 ± 2.6 | 56.6 ± 5.1 |
| PKC412 | ||
| 50 nM | 96.4 ± 2.2 | 82.2 ± 4.8 |
| 100 nM | 96.0 ± 2.7 | 79.2 ± 5.3 |
Drug, dose . | WT FLT3 . | FLT3/ITD . |
|---|---|---|
| CEP-701 | ||
| 20 nM | 76.1 ± 2.0 | 66.4 ± 4.8 |
| 50 nM | 60.8 ± 2.6 | 56.6 ± 5.1 |
| PKC412 | ||
| 50 nM | 96.4 ± 2.2 | 82.2 ± 4.8 |
| 100 nM | 96.0 ± 2.7 | 79.2 ± 5.3 |
Primary AML samples harboring wild-type FLT3 (25 samples) and FLT3/ITD mutations (21 samples) were incubated with increasing concentrations of CEP-701 or PKC412, and the MTT assay was performed after 72 hours. The results are expressed as percent untreated control, and the values for all results from a given concentration point are expressed as a mean ± SEM.
WT indicates wild-type